Peter J. Mogayzel - Concepedia

Author

Peter J. Mogayzel

Also Known As

P J Mogayzel, P. J. Mogayzel, P. Mogayzel, P.J. Mogayzel, Peter J. Mogayzel, Peter J Mogayzel, Peter J. Mogayzel, Peter J. Mogayzel,, Peter J. Mogayzel, Jr., Peter Mogayzel

155

Publications

7.1K

Citations

H-Index

111

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine University of Pittsburgh Baylor College of Medicine Stanford University

About

Peter J. Mogayzel is an author at Johns Hopkins University specializing in medicine, pediatrics, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	31	1.8K
2	Health Sciences	4	4	174
3	Natural Sciences	2	2	30
4	Allergy	2	2	44
5	Public Health	1	1	39

Peter J. Mogayzel

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Cystic Fibrosis Pulmonary Guidelines Patrick A. Flume, Brian O’Sullivan, Karen A. Robinson, American Journal of Respiratory and Critical Care Medicine	2007	1K
Diagnostic Sweat Testing: The Cystic Fibrosis Foundation Guidelines Vicky A. LeGrys, James R. Yankaskas, Lynne M. Quittell, The Journal of Pediatrics Point-of-care TestingMedicineDiagnostic TestDiagnostic CriterionDiagnosis	2007	293
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study Margaret Rosenfeld, Claire Wainwright, Mark Higgins, The Lancet Respiratory Medicine MedicineCftr Gating MutationPediatricsIvacaftor Treatment	2018	262
Cystic Fibrosis Pulmonary Guidelines Patrick A. Flume, Peter J. Mogayzel, Karen A. Robinson, American Journal of Respiratory and Critical Care Medicine	2010	245
Longitudinal association between medication adherence and lung health in people with cystic fibrosis Michelle N. Eakin, Andrew Bilderback, Michael Boyle, Journal of Cystic Fibrosis Preventive MedicineChronic Disease ManagementMedication AdherencePulmonary CarePulmonary Fibrosis	2011	236
Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity Faheem Farooq, Peter J. Mogayzel, Sophie Lanzkron, JAMA Network Open	2020	175
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results Noah Lechtzin, Nicole Mayer-Hamblett, Natalie E. West, American Journal of Respiratory and Critical Care Medicine	2017	122
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell, The Lancet Respiratory Medicine MedicineHypertonic SalineDornase AlfaPulmonary Fibrosis	2022	116
Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial Félix Ratjen, Stephanie D. Davis, Sanja Stanojevic, The Lancet Respiratory Medicine PediatricsPediatric Lung DiseasePlacebo-controlled TrialMedicineHypertonic Saline	2019	111
Location and Duration of Treatment of Cystic Fibrosis Respiratory Exacerbations Do Not Affect Outcomes Joseph M. Collaco, Deanna Green, Garry R. Cutting, American Journal of Respiratory and Critical Care Medicine	2010	108

Page 1